RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (cIAPs) in RANK-positive breast cancer cells

OBJECTIVE: Between 65% and 75% of patients with metastatic breast cancer will have decreased 5-year survival and increased morbidity due to cancer relapse in bone. At this stage of disease treatment is palliative, but tumor-targeted compounds could add to the benefits of anti-resorptive agents, impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Casimiro, S., Alho, I., Bettencourt, M., Pires, R., Lipton, A., Costa, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723389/
https://www.ncbi.nlm.nih.gov/pubmed/26909281
http://dx.doi.org/10.1016/j.jbo.2013.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723389/
https://www.ncbi.nlm.nih.gov/pubmed/26909281
http://dx.doi.org/10.1016/j.jbo.2013.07.001

Ejemplares similares